Omicron vaccine, active against Corona subvariants BA.4 and BA.5, has now been approved by the EMA

Spread the love

Read Time:1 Minute, 27 Second

The European Medicines Agency (EMA) on Monday approved a Corona vaccine that is also active against Omicron subvariants BA.4 and BA.5.
EMA granted approval to bivalent omicron vaccine
The Amsterdam-based EMA said the approval of this Biontech/Pfizer vaccine once again expands the vaccine arsenal to protect against covid-19 as fall and winter approach.
The vaccine now approved is a so-called bivalent corona vaccine, designed to defend against both the original form of coronavirus and BA.4 and BA.5, the currently dominant subtypes of the omicron variant of coronavirus.

On September 1, the EMA had approved the first Corona vaccines adapted to the Omicron variant. The two vaccines in question, from Biontech/Pfizer and Moderna, target Omikron subvariant BA.1.
Up to this point, vaccination in the EU has been with Corona vaccines licensed about 20 months ago. They also provide some protection against the Omicron variant.
Vaccination recommendation from NIG expected in coming days
For Austria, this means that following approval by the European Commission, the National Immunization Panel (NIG) will soon issue its recommendations. These should already be available in the coming days. The first delivery of this variant vaccine to Austria can be expected as early as next week, he said.
“With the new adapted vaccines, we have additional tools at our disposal to be able to protect the population against severe corona disease,” said Health Minister Johannes Rauch (Greens) in a statement. “For optimal sustained protection, they are particularly important for booster vaccinations. The vaccinations are one of the most important measures to ensure that we get through the fall and winter well.” Rauch appealed, “Get your booster shot in the coming weeks and protect yourself.”